Mithra Announces Launch of Warrant Exercise Period


Mithra Pharmaceuticals (Euronext Brussels: MITRA), a company specialized in Women’s Health, today announces the launch of an exercise period of its warrant plan initiated on 2 March 2015.

The warrant plan issued 1,089 warrants, entitling their holders to subscribe for a total number of  1,796,850 securities carrying voting rights (all ordinary shares), and exercisable in principle as from 1  January 2019. Pursuant to the conditions of the warrant plan, the current warrant exercise is  triggered by the capital increase by way of a Private Placement executed on June 23, 2017, and  approved by Mithra’s Board of Directors.

Based on the information received from warrant holders, Mithra expects to issue a maximum of 724,350 new shares which would result in a total share count of 34,967,081 ordinary shares. The  outstanding warrants would remain exercisable as from 1 January 2019.


Mithra (Euronext: MITRA) is dedicated to providing innovation and choice in Women’s Health, with a  particular focus on fertility, contraception and menopause. Mithra’s goal is to develop new and  improved products that meet women’s needs for better safety and convenience. Its two lead  development candidates – a fifth generation oral contraceptive Estelle® and next-generation  hormone therapy Donesta® - are built on Mithra’s unique natural estrogen platform, E4 (Estetrol).  Mithra also develops, manufactures and markets complex therapeutics and offers partners a  complete spectrum of research, development and specialist manufacturing at its CDMO. Mithra was  founded in 1999 as a spin-off from the University of Liège by Mr. François Fornieri and Prof. Dr. JeanMichel Foidart. Mithra is headquartered in Liège, Belgium. Further information can be found at:



Interested in a regular update of the Life Sciences and biotech sector in Flanders?